The Anti-tumor Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-tumor Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Anti-tumor Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Anti-tumor Drug Market Report

Report Metric	Details
Report Name	Anti-tumor Drug Market
Segment by Type	Cytotoxic Drugs Non-cytotoxic Drugs
Segment by Application	Alkylating Agents Anti-Metabolism Drugs Platinum Antineoplastic Agents Anthracycline Antitumor Drugs Microtubule Stabilizer Endocrine Therapy Drugs Immunotherapy Drugs Gene Therapy Drugs Targeted Antineoplastic Drugs
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co, Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-tumor Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Anti-tumor Drug Market report?

Ans: The main players in the Anti-tumor Drug Market are Roche, Novartis, Celgene, Bristol-Myers Squibb, Amgen, Johnson & Johnson, Pfizer, Takeda, Eli Lilly, AstraZeneca, Astellas, Merck & Co, Sanofi, Bayer, Biogen Idec, Eisai, Teva, Otsuka

What are the Application segmentation covered in the Anti-tumor Drug Market report?

Ans: The Applications covered in the Anti-tumor Drug Market report are Alkylating Agents, Anti-Metabolism Drugs, Platinum Antineoplastic Agents, Anthracycline Antitumor Drugs, Microtubule Stabilizer, Endocrine Therapy Drugs, Immunotherapy Drugs, Gene Therapy Drugs, Targeted Antineoplastic Drugs

What are the Type segmentation covered in the Anti-tumor Drug Market report?

Ans: The Types covered in the Anti-tumor Drug Market report are Cytotoxic Drugs, Non-cytotoxic Drugs

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Anti-tumor Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Cytotoxic Drugs

1.2.3 Non-cytotoxic Drugs

1.3 Market by Application

1.3.1 Global Anti-tumor Drug Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Alkylating Agents

1.3.3 Anti-Metabolism Drugs

1.3.4 Platinum Antineoplastic Agents

1.3.5 Anthracycline Antitumor Drugs

1.3.6 Microtubule Stabilizer

1.3.7 Endocrine Therapy Drugs

1.3.8 Immunotherapy Drugs

1.3.9 Gene Therapy Drugs

1.3.10 Targeted Antineoplastic Drugs

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Anti-tumor Drug Market Perspective (2019-2030)

2.2 Anti-tumor Drug Growth Trends by Region

2.2.1 Global Anti-tumor Drug Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Anti-tumor Drug Historic Market Size by Region (2019-2024)

2.2.3 Anti-tumor Drug Forecasted Market Size by Region (2025-2030)

2.3 Anti-tumor Drug Market Dynamics

2.3.1 Anti-tumor Drug Industry Trends

2.3.2 Anti-tumor Drug Market Drivers

2.3.3 Anti-tumor Drug Market Challenges

2.3.4 Anti-tumor Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Anti-tumor Drug Players by Revenue

3.1.1 Global Top Anti-tumor Drug Players by Revenue (2019-2024)

3.1.2 Global Anti-tumor Drug Revenue Market Share by Players (2019-2024)

3.2 Global Anti-tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Anti-tumor Drug Revenue

3.4 Global Anti-tumor Drug Market Concentration Ratio

3.4.1 Global Anti-tumor Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Anti-tumor Drug Revenue in 2023

3.5 Anti-tumor Drug Key Players Head office and Area Served

3.6 Key Players Anti-tumor Drug Product Solution and Service

3.7 Date of Enter into Anti-tumor Drug Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Anti-tumor Drug Breakdown Data by Type

4.1 Global Anti-tumor Drug Historic Market Size by Type (2019-2024)

4.2 Global Anti-tumor Drug Forecasted Market Size by Type (2025-2030)

5 Anti-tumor Drug Breakdown Data by Application

5.1 Global Anti-tumor Drug Historic Market Size by Application (2019-2024)

5.2 Global Anti-tumor Drug Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Anti-tumor Drug Market Size (2019-2030)

6.2 North America Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Anti-tumor Drug Market Size by Country (2019-2024)

6.4 North America Anti-tumor Drug Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Anti-tumor Drug Market Size (2019-2030)

7.2 Europe Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Anti-tumor Drug Market Size by Country (2019-2024)

7.4 Europe Anti-tumor Drug Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Anti-tumor Drug Market Size (2019-2030)

8.2 Asia-Pacific Anti-tumor Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Anti-tumor Drug Market Size by Region (2019-2024)

8.4 Asia-Pacific Anti-tumor Drug Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Anti-tumor Drug Market Size (2019-2030)

9.2 Latin America Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Anti-tumor Drug Market Size by Country (2019-2024)

9.4 Latin America Anti-tumor Drug Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Anti-tumor Drug Market Size (2019-2030)

10.2 Middle East & Africa Anti-tumor Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Anti-tumor Drug Market Size by Country (2019-2024)

10.4 Middle East & Africa Anti-tumor Drug Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Detail

11.1.2 Roche Business Overview

11.1.3 Roche Anti-tumor Drug Introduction

11.1.4 Roche Revenue in Anti-tumor Drug Business (2019-2024)

11.1.5 Roche Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis Anti-tumor Drug Introduction

11.2.4 Novartis Revenue in Anti-tumor Drug Business (2019-2024)

11.2.5 Novartis Recent Development

11.3 Celgene

11.3.1 Celgene Company Detail

11.3.2 Celgene Business Overview

11.3.3 Celgene Anti-tumor Drug Introduction

11.3.4 Celgene Revenue in Anti-tumor Drug Business (2019-2024)

11.3.5 Celgene Recent Development

11.4 Bristol-Myers Squibb

11.4.1 Bristol-Myers Squibb Company Detail

11.4.2 Bristol-Myers Squibb Business Overview

11.4.3 Bristol-Myers Squibb Anti-tumor Drug Introduction

11.4.4 Bristol-Myers Squibb Revenue in Anti-tumor Drug Business (2019-2024)

11.4.5 Bristol-Myers Squibb Recent Development

11.5 Amgen

11.5.1 Amgen Company Detail

11.5.2 Amgen Business Overview

11.5.3 Amgen Anti-tumor Drug Introduction

11.5.4 Amgen Revenue in Anti-tumor Drug Business (2019-2024)

11.5.5 Amgen Recent Development

11.6 Johnson & Johnson

11.6.1 Johnson & Johnson Company Detail

11.6.2 Johnson & Johnson Business Overview

11.6.3 Johnson & Johnson Anti-tumor Drug Introduction

11.6.4 Johnson & Johnson Revenue in Anti-tumor Drug Business (2019-2024)

11.6.5 Johnson & Johnson Recent Development

11.7 Pfizer

11.7.1 Pfizer Company Detail

11.7.2 Pfizer Business Overview

11.7.3 Pfizer Anti-tumor Drug Introduction

11.7.4 Pfizer Revenue in Anti-tumor Drug Business (2019-2024)

11.7.5 Pfizer Recent Development

11.8 Takeda

11.8.1 Takeda Company Detail

11.8.2 Takeda Business Overview

11.8.3 Takeda Anti-tumor Drug Introduction

11.8.4 Takeda Revenue in Anti-tumor Drug Business (2019-2024)

11.8.5 Takeda Recent Development

11.9 Eli Lilly

11.9.1 Eli Lilly Company Detail

11.9.2 Eli Lilly Business Overview

11.9.3 Eli Lilly Anti-tumor Drug Introduction

11.9.4 Eli Lilly Revenue in Anti-tumor Drug Business (2019-2024)

11.9.5 Eli Lilly Recent Development

11.10 AstraZeneca

11.10.1 AstraZeneca Company Detail

11.10.2 AstraZeneca Business Overview

11.10.3 AstraZeneca Anti-tumor Drug Introduction

11.10.4 AstraZeneca Revenue in Anti-tumor Drug Business (2019-2024)

11.10.5 AstraZeneca Recent Development

11.11 Astellas

11.11.1 Astellas Company Detail

11.11.2 Astellas Business Overview

11.11.3 Astellas Anti-tumor Drug Introduction

11.11.4 Astellas Revenue in Anti-tumor Drug Business (2019-2024)

11.11.5 Astellas Recent Development

11.12 Merck & Co

11.12.1 Merck & Co Company Detail

11.12.2 Merck & Co Business Overview

11.12.3 Merck & Co Anti-tumor Drug Introduction

11.12.4 Merck & Co Revenue in Anti-tumor Drug Business (2019-2024)

11.12.5 Merck & Co Recent Development

11.13 Sanofi

11.13.1 Sanofi Company Detail

11.13.2 Sanofi Business Overview

11.13.3 Sanofi Anti-tumor Drug Introduction

11.13.4 Sanofi Revenue in Anti-tumor Drug Business (2019-2024)

11.13.5 Sanofi Recent Development

11.14 Bayer

11.14.1 Bayer Company Detail

11.14.2 Bayer Business Overview

11.14.3 Bayer Anti-tumor Drug Introduction

11.14.4 Bayer Revenue in Anti-tumor Drug Business (2019-2024)

11.14.5 Bayer Recent Development

11.15 Biogen Idec

11.15.1 Biogen Idec Company Detail

11.15.2 Biogen Idec Business Overview

11.15.3 Biogen Idec Anti-tumor Drug Introduction

11.15.4 Biogen Idec Revenue in Anti-tumor Drug Business (2019-2024)

11.15.5 Biogen Idec Recent Development

11.16 Eisai

11.16.1 Eisai Company Detail

11.16.2 Eisai Business Overview

11.16.3 Eisai Anti-tumor Drug Introduction

11.16.4 Eisai Revenue in Anti-tumor Drug Business (2019-2024)

11.16.5 Eisai Recent Development

11.17 Teva

11.17.1 Teva Company Detail

11.17.2 Teva Business Overview

11.17.3 Teva Anti-tumor Drug Introduction

11.17.4 Teva Revenue in Anti-tumor Drug Business (2019-2024)

11.17.5 Teva Recent Development

11.18 Otsuka

11.18.1 Otsuka Company Detail

11.18.2 Otsuka Business Overview

11.18.3 Otsuka Anti-tumor Drug Introduction

11.18.4 Otsuka Revenue in Anti-tumor Drug Business (2019-2024)

11.18.5 Otsuka Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

List of Tables

Table 1. Global Anti-tumor Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Cytotoxic Drugs

Table 3. Key Players of Non-cytotoxic Drugs

Table 4. Global Anti-tumor Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Anti-tumor Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Anti-tumor Drug Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Anti-tumor Drug Market Share by Region (2019-2024)

Table 8. Global Anti-tumor Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Anti-tumor Drug Market Share by Region (2025-2030)

Table 10. Anti-tumor Drug Market Trends

Table 11. Anti-tumor Drug Market Drivers

Table 12. Anti-tumor Drug Market Challenges

Table 13. Anti-tumor Drug Market Restraints

Table 14. Global Anti-tumor Drug Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Anti-tumor Drug Market Share by Players (2019-2024)

Table 16. Global Top Anti-tumor Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-tumor Drug as of 2023)

Table 17. Ranking of Global Top Anti-tumor Drug Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Anti-tumor Drug Revenue (CR5 and HHI) & (2019-2024)

Table 19. Key Players Headquarters and Area Served

Table 20. Key Players Anti-tumor Drug Product Solution and Service

Table 21. Date of Enter into Anti-tumor Drug Market

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Anti-tumor Drug Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Anti-tumor Drug Revenue Market Share by Type (2019-2024)

Table 25. Global Anti-tumor Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Anti-tumor Drug Revenue Market Share by Type (2025-2030)

Table 27. Global Anti-tumor Drug Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Anti-tumor Drug Revenue Market Share by Application (2019-2024)

Table 29. Global Anti-tumor Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Anti-tumor Drug Revenue Market Share by Application (2025-2030)

Table 31. North America Anti-tumor Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Anti-tumor Drug Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Anti-tumor Drug Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Anti-tumor Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Anti-tumor Drug Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Anti-tumor Drug Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Anti-tumor Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Anti-tumor Drug Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Anti-tumor Drug Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Anti-tumor Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Anti-tumor Drug Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Anti-tumor Drug Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Anti-tumor Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Anti-tumor Drug Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Anti-tumor Drug Market Size by Country (2025-2030) & (US$ Million)

Table 46. Roche Company Detail

Table 47. Roche Business Overview

Table 48. Roche Anti-tumor Drug Product

Table 49. Roche Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 50. Roche Recent Development

Table 51. Novartis Company Detail

Table 52. Novartis Business Overview

Table 53. Novartis Anti-tumor Drug Product

Table 54. Novartis Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 55. Novartis Recent Development

Table 56. Celgene Company Detail

Table 57. Celgene Business Overview

Table 58. Celgene Anti-tumor Drug Product

Table 59. Celgene Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 60. Celgene Recent Development

Table 61. Bristol-Myers Squibb Company Detail

Table 62. Bristol-Myers Squibb Business Overview

Table 63. Bristol-Myers Squibb Anti-tumor Drug Product

Table 64. Bristol-Myers Squibb Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 65. Bristol-Myers Squibb Recent Development

Table 66. Amgen Company Detail

Table 67. Amgen Business Overview

Table 68. Amgen Anti-tumor Drug Product

Table 69. Amgen Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 70. Amgen Recent Development

Table 71. Johnson & Johnson Company Detail

Table 72. Johnson & Johnson Business Overview

Table 73. Johnson & Johnson Anti-tumor Drug Product

Table 74. Johnson & Johnson Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 75. Johnson & Johnson Recent Development

Table 76. Pfizer Company Detail

Table 77. Pfizer Business Overview

Table 78. Pfizer Anti-tumor Drug Product

Table 79. Pfizer Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 80. Pfizer Recent Development

Table 81. Takeda Company Detail

Table 82. Takeda Business Overview

Table 83. Takeda Anti-tumor Drug Product

Table 84. Takeda Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 85. Takeda Recent Development

Table 86. Eli Lilly Company Detail

Table 87. Eli Lilly Business Overview

Table 88. Eli Lilly Anti-tumor Drug Product

Table 89. Eli Lilly Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 90. Eli Lilly Recent Development

Table 91. AstraZeneca Company Detail

Table 92. AstraZeneca Business Overview

Table 93. AstraZeneca Anti-tumor Drug Product

Table 94. AstraZeneca Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 95. AstraZeneca Recent Development

Table 96. Astellas Company Detail

Table 97. Astellas Business Overview

Table 98. Astellas Anti-tumor Drug Product

Table 99. Astellas Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 100. Astellas Recent Development

Table 101. Merck & Co Company Detail

Table 102. Merck & Co Business Overview

Table 103. Merck & Co Anti-tumor Drug Product

Table 104. Merck & Co Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 105. Merck & Co Recent Development

Table 106. Sanofi Company Detail

Table 107. Sanofi Business Overview

Table 108. Sanofi Anti-tumor Drug Product

Table 109. Sanofi Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 110. Sanofi Recent Development

Table 111. Bayer Company Detail

Table 112. Bayer Business Overview

Table 113. Bayer Anti-tumor Drug Product

Table 114. Bayer Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 115. Bayer Recent Development

Table 116. Biogen Idec Company Detail

Table 117. Biogen Idec Business Overview

Table 118. Biogen Idec Anti-tumor Drug Product

Table 119. Biogen Idec Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 120. Biogen Idec Recent Development

Table 121. Eisai Company Detail

Table 122. Eisai Business Overview

Table 123. Eisai Anti-tumor Drug Product

Table 124. Eisai Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 125. Eisai Recent Development

Table 126. Teva Company Detail

Table 127. Teva Business Overview

Table 128. Teva Anti-tumor Drug Product

Table 129. Teva Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 130. Teva Recent Development

Table 131. Otsuka Company Detail

Table 132. Otsuka Business Overview

Table 133. Otsuka Anti-tumor Drug Product

Table 134. Otsuka Revenue in Anti-tumor Drug Business (2019-2024) & (US$ Million)

Table 135. Otsuka Recent Development

Table 136. Research Programs/Design for This Report

Table 137. Key Data Information from Secondary Sources

Table 138. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Anti-tumor Drug Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Anti-tumor Drug Market Share by Type: 2023 VS 2030

Figure 3. Cytotoxic Drugs Features

Figure 4. Non-cytotoxic Drugs Features

Figure 5. Global Anti-tumor Drug Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 6. Global Anti-tumor Drug Market Share by Application: 2023 VS 2030

Figure 7. Alkylating Agents Case Studies

Figure 8. Anti-Metabolism Drugs Case Studies

Figure 9. Platinum Antineoplastic Agents Case Studies

Figure 10. Anthracycline Antitumor Drugs Case Studies

Figure 11. Microtubule Stabilizer Case Studies

Figure 12. Endocrine Therapy Drugs Case Studies

Figure 13. Immunotherapy Drugs Case Studies

Figure 14. Gene Therapy Drugs Case Studies

Figure 15. Targeted Antineoplastic Drugs Case Studies

Figure 16. Anti-tumor Drug Report Years Considered

Figure 17. Global Anti-tumor Drug Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 18. Global Anti-tumor Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 19. Global Anti-tumor Drug Market Share by Region: 2023 VS 2030

Figure 20. Global Anti-tumor Drug Market Share by Players in 2023

Figure 21. Global Top Anti-tumor Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-tumor Drug as of 2023)

Figure 22. The Top 10 and 5 Players Market Share by Anti-tumor Drug Revenue in 2023

Figure 23. North America Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. North America Anti-tumor Drug Market Share by Country (2019-2030)

Figure 25. United States Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Canada Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Europe Anti-tumor Drug Market Share by Country (2019-2030)

Figure 29. Germany Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. France Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. U.K. Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Italy Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Russia Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Nordic Countries Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Asia-Pacific Anti-tumor Drug Market Share by Region (2019-2030)

Figure 37. China Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Japan Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. South Korea Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Southeast Asia Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. India Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Australia Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Latin America Anti-tumor Drug Market Share by Country (2019-2030)

Figure 45. Mexico Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Brazil Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Middle East & Africa Anti-tumor Drug Market Share by Country (2019-2030)

Figure 49. Turkey Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Anti-tumor Drug Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Roche Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 52. Novartis Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 53. Celgene Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 54. Bristol-Myers Squibb Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 55. Amgen Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 56. Johnson & Johnson Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 57. Pfizer Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 58. Takeda Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 59. Eli Lilly Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 60. AstraZeneca Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 61. Astellas Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 62. Merck & Co Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 63. Sanofi Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 64. Bayer Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 65. Biogen Idec Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 66. Eisai Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 67. Teva Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 68. Otsuka Revenue Growth Rate in Anti-tumor Drug Business (2019-2024)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions